The Swedish Drug Development Pipeline 2014
| Reference number | |
| Coordinator | SwedenBIO Service AB |
| Funding from Vinnova | SEK 100 000 |
| Project duration | December 2013 - November 2014 |
| Status | Completed |
Important results from the project
The goal was to collect information about the project portfolio of future drugs in Swedish biotech and pharmaceutical companies and visualize the state of the industry and the need for support. The aim was to gain insight of the project pipeline with focus in projects that have reached the clinic (Phase I-III). Both goal and aim has have successfully been meet.
Expected long term effects
A report was produced according to plan. The report was launched at SwedenBIO CEO Summit and in conjunction to that it attracted attention in the media.
Approach and implementation
Initially, research was done in order to identify Swedish pharmaceutical- and biotech companies developing new drugs. The companies were invited to fill in an online questionnaire with questions about their projects. About one hundred companies were identified. The survey was conducted during the second half of 2014 and were compiled during the autumn. The report was released at SwedenBIO CEO Summit. In conjunction with the release the report attracted attention in media e.g. Life Science Sweden, six nyhetsbyrå, Läkemedelsvärlden och Läkemedelsmarknaden.